Jacobs Levy Equity Management, Inc Regenxbio Inc. Transaction History

Jacobs Levy Equity Management, Inc

$23.2 Billion
Q2 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 152,437 shares of RGNX stock, worth $1.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

152,437

Previous 292,341 47.86%

Holding current value

$1.6 Million

Previous $6.16 Million 71.05%

% of portfolio

0.01%

Previous 0.03%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.51 - $21.53 $1.61 Million - $3.01 Million	-139,904 Reduced 47.86%	152,437 $1.78 Million
Q1 2024 May 15, 2024	SELL	$12.17 - $24.61 $4.9 Million - $9.91 Million	-402,843 Reduced 57.95%	292,341 $6.16 Million
Q4 2023 Feb 14, 2024	BUY	$12.89 - $20.82 $1.71 Million - $2.76 Million	132,793 Added 23.61%	695,184 $12.5 Million
Q3 2023 Nov 16, 2023	BUY	$16.46 - $19.99 $24,574 - $29,845	1,493 Added 0.27%	562,391 $9.26 Million
Q2 2023 Aug 14, 2023	SELL	$17.23 - $21.71 $1.23 Million - $1.55 Million	-71,480 Reduced 11.3%	560,898 $11.2 Million
Q1 2023 May 15, 2023	BUY	$18.08 - $24.55 $10.9 Million - $14.9 Million	605,255 Added 2231.52%	632,378 $12 Million
Q4 2022 Feb 14, 2023	BUY	$20.4 - $24.73 $337,232 - $408,811	16,531 Added 156.07%	27,123 $615,000
Q3 2022 Nov 15, 2022	SELL	$22.29 - $35.04 $3.29 Million - $5.17 Million	-147,660 Reduced 93.31%	10,592 $280,000
Q2 2022 Aug 15, 2022	SELL	$19.35 - $35.04 $322,371 - $583,766	-16,660 Reduced 9.52%	158,252 $3.91 Million
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $4.31 Million - $6 Million	174,912 New	174,912 $5.81 Million
Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $5.22 Million - $8.2 Million	-179,521 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $387,669 - $483,452	-11,943 Reduced 6.24%	179,521 $6.97 Million
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $5.53 Million - $8.21 Million	164,416 Added 607.87%	191,464 $6.53 Million
Q4 2020 Feb 16, 2021	SELL	$26.52 - $49.35 $40,257 - $74,913	-1,518 Reduced 5.31%	27,048 $1.23 Million
Q3 2020 Nov 16, 2020	SELL	$27.01 - $40.26 $142,099 - $211,807	-5,261 Reduced 15.55%	28,566 $786,000
Q2 2020 Aug 17, 2020	BUY	$27.75 - $43.44 $938,699 - $1.47 Million	33,827 New	33,827 $1.25 Million

Others Institutions Holding RGNX

# of Institutions

191

Shares Held

43.5M

Call Options Held

58.9K

Put Options Held

58.4K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $453M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Regenxbio Inc. Transaction History